How should inotuzumab ozogamicin be administered, monitored, and what are the contraindications and alternatives for adult patients with relapsed or refractory B‑cell acute lymphoblastic leukemia?

Inotuzumab Ozogamicin in Relapsed/Refractory B-cell ALL

Inotuzumab ozogamicin (InO) is FDA-approved for relapsed or refractory CD22-positive B-cell precursor ALL in adults and pediatric patients ≥1 year old, administered at 1.8 mg/m² per cycle divided over 3 doses (Day 1: 0.8 mg/m², Days 8 and 15: 0.5 mg/m² each) for Cycle 1, with dose adjustments based on response in subsequent cycles 1.

Administration Protocol

Dosing Schedule

Cycle 1 (21-28 days):

• Day 1: 0.8 mg/m² IV
• Day 8: 0.5 mg/m² IV (±2 days, minimum 6 days between doses)
• Day 15: 0.5 mg/m² IV (±2 days)
• May extend to 28 days if CR/CRi achieved or for toxicity recovery 1

Subsequent Cycles (28 days):

• If CR/CRi achieved: 0.5 mg/m² on Days 1,8, and 15 (total 1.5 mg/m²/cycle)
• If no CR/CRi: Continue 0.8 mg/m² on Day 1,0.5 mg/m² on Days 8 and 15 (total 1.8 mg/m²/cycle)
• Discontinue if no CR/CRi after 3 cycles 1

Treatment Duration:

• For HSCT candidates: 2 cycles recommended; consider 3rd cycle only if MRD negativity not achieved 1
• For non-HSCT patients: Up to 6 cycles maximum 1

Pre-medication Requirements

Administer before each dose to prevent infusion reactions 1.

Monitoring Requirements

Hepatotoxicity Surveillance (Critical)

Before each dose:

• Total bilirubin
• AST/ALT
• Alkaline phosphatase 1

VOD/SOS risk assessment:

• Monitor for jaundice, hepatomegaly, rapid weight gain, ascites
• Highest risk: post-HSCT (11-28.6% incidence) 2, 3
• Risk factors include: ongoing/prior liver disease, prior HSCT, age >60 years, later salvage lines, multiple InO cycles, conditioning with 2 alkylating agents, bilirubin ≥ULN pre-HSCT 1

Hematologic Monitoring

Weekly during treatment:

• Complete blood count with differential
• Platelet count
• Most common grade 3-4 events: thrombocytopenia (81%), infections (52-69%), neutropenia 4

Cardiac Monitoring

• Baseline and periodic ECG monitoring
• QTcF increases ≥60 msec occurred in 3% of patients 1
• Monitor for QTc prolongation, especially with concomitant QT-prolonging medications

MRD Assessment

• Evaluate after Cycle 2 for treatment response
• 78.4% of InO responders achieved MRD negativity (<0.01% marrow blasts) versus 28.1% with standard therapy 5

Contraindications and Dose Modifications

Absolute Contraindications

• Active VOD/SOS 1
• Severe hepatic impairment (insufficient data for total bilirubin >1.5× ULN) 1

Dose Interruption/Reduction Required For:

• Grade 3-4 liver enzyme elevations
• Total bilirubin >1.5× ULN
• Grade 3-4 non-hematologic toxicity
• Permanently discontinue if VOD occurs 1

Special Populations

• Renal impairment: No dose adjustment needed for CLcr ≥15 mL/min; unknown for end-stage renal disease 1
• Pediatric patients ≥1 year: ~30% higher AUC than adults at recommended dosing; same dose schedule applies 1

HSCT Considerations (Critical Safety Issue)

Timing is crucial to minimize VOD risk:

• Allow adequate interval between last InO dose and HSCT conditioning
• Avoid conditioning regimens with 2 alkylating agents if possible 1
• Post-HSCT VOD rates: 14-28.6% in various studies 2, 3
• Day 100 post-HSCT mortality higher with InO versus chemotherapy 1

Bridge-to-transplant efficacy:

• 39.6% of InO patients proceeded directly to HSCT after CR/CRi versus 10.5% with standard therapy 3
• 79-80% successfully bridged to alloSCT in real-world studies 6

Alternative Dosing Strategy

For patients at higher VOD risk proceeding to HSCT:

• Consider starting dose of 1.2 mg/m²/cycle (0.5 mg/m² on Days 1,8,15)
• Phase 4 study showed comparable efficacy: CR/CRi 71.9% versus 68.4% with standard 1.8 mg/m² dose
• Post-HSCT VOD rates similar: 25.8% versus 16.7% 2

Alternative Therapies

Blinatumomab

• CD19-directed bispecific T-cell engager
• Preferred in low disease burden/MRD-positive settings
• 69% CR rate in overt relapse, superior T-cell preservation 6, 7
• Lower VOD risk, different toxicity profile (cytokine release syndrome, neurotoxicity)

Sequential Approach

• InO induction followed by blinatumomab consolidation shows promise
• Chemotherapy-free regimen in elderly: 85% CR with InO, 97% cumulative CR after blinatumomab 4
• Optimizes cytoreduction (InO) then immune engagement (blinatumomab) 7

Standard Chemotherapy

• Reserved for InO-ineligible patients (CD22-negative, severe hepatic dysfunction)
• Inferior outcomes: 29.4% CR rate versus 80.7% with InO 5

Key Clinical Pearls

Efficacy benchmarks:

• CR/CRi rate: 73.8-83.3% 3, 5
• MRD negativity: 78.4-94.7% of responders 5, 8
• Median OS: 7.7 months versus 6.2 months with chemotherapy 3

Common pitfalls to avoid:

• Proceeding to HSCT without adequate interval from last InO dose
• Using dual alkylating agent conditioning regimens post-InO
• Continuing beyond 3 cycles without CR/CRi
• Inadequate hepatic monitoring frequency

Treatment selection algorithm:

• High disease burden → InO preferred for cytoreduction
• Low disease burden/MRD-positive → Consider blinatumomab
• HSCT candidate with high VOD risk → Consider 1.2 mg/m² starting dose
• Post-InO relapse → Blinatumomab or CAR-T therapy 7